About - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

The 2023 Annual
PRIMO Meeting

The PRIMO meeting Co-Chairs, Steering Committee, and Education Committee have curated an agenda to meet the educational needs of all attendees and will focus on the following key areas:
  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
12:00 PM – 7:00 PM
Registration
6:30 PM – 8:00 PM
Welcome reception at the Hilton Hawaiian Village
Join us in honoring the 2023 Women in Oncology Award winners

6:30 AM – 3:00 PM
Exhibits open
7:00 AM – 7:05 AM
Meeting Welcome
7:05 AM – 7:10 AM
Program Overview
Hematologic Malignancies – Session Chair – Julie M. Vose, MD, MBA
7:10 AM – 7:30 AM
Update on Novel Therapies for NHL
7:30 AM – 7:50 AM
Role of Immunotherapy in Myeloma
7:50 AM – 8:10 AM
AML: Where Are We Now and Where Are We Going?
8:10 AM – 8:30 AM
Update on Therapy Options for Untreated and Relapsed CLL
Product Theater
9:00 AM – 9:45 AM
Product Theater Breakfast Showcase (Non-CE)
9:45 AM – 10:00 AM
Visit Exhibits
Multidisciplinary Approach to Cancer – Session Chair – Jorge J. García, PharmD, MS, MHA, MBA, FACHE
10:00 AM – 10:20 AM
Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors
10:20 AM – 10:40 AM
Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains
10:40 AM – 11:00 AM
Current Status of CAR-T Therapy in Hematology
Product Theater
11:30 AM – 12:15 PM
Product Theater Lunch Showcase (Non-CE)
12:15 PM – 12:30 PM
Visit Exhibits
Gastrointestinal Malignancies – Session Chair – Rachna T. Shroff, MD, MS
12:30 PM – 12:50 PM
Pancreatic Cancer: Are We Finally Making Progress?
12:50 PM – 1:10 PM
Novel Immunotherapy Approaches in Hepatobiliary Malignancies
1:10 PM – 1:30 PM
Q&A I Panel Discussion
Evening Reception*
5:30 PM – 7:00 PM
Sunset Mingle Networking Event (*by invite only)

6:30 AM – 3:00 PM
Exhibits open
7:00 AM – 7:05 AM
Welcome and Day 2 Program Overview
Keynote Lectures – Session Chair - Sanjiv S. Agarwala, MD
7:05 AM – 7:25 AM
Melanoma as a Paradigm for the Future of Immunotherapy
7:25 AM – 7:30 AM
Q&A
7:30 AM – 7:50 AM
Liquid Biopsy: Advances in the Last Decade and Future Directions
7:50 AM – 7:55 AM
Q&A
Product Theater
8:00 AM – 8:45 AM
Product Theater Breakfast Showcase (Non-CE)
8:45 AM – 9:00 AM
Visit Exhibits
Lung & Aerodigestive Cancer – Session Chair – Luis E. Raez, MD, FACP, FCCP
9:00 AM – 9:15 AM
Approach to NSCLC Without Targetable Mutations
9:15 AM – 9:30 AM
Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)
9:30 AM – 9:45 AM
Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)
9:45 AM – 10:00 AM
Adjuvant and Neo-adjuvant Therapy for Lung Cancer
10:00 AM – 11:00 AM
Lung Cancer Tumor Board with CEN:
1 NSCLC Case (Patel), 1 SCLC Case (Subramanian), 1 Neoadjuvant Lung Cancer Case (Raez), 1 Stage III Case (Santos)
Product Theater
11:00 AM – 11:45 AM
Product Theater Lunch Showcase (Non-CE)
11:45 AM – 12:00 PM
Desserts | Visit Exhibits
Genitourinary/HNC Cancer – Session Chair – Edgardo S. Santos Castillero, MD, FACP
12:00 PM – 12:20 PM
Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond
12:20 PM – 12:40 PM
Role of Immunotherapy in HNC
12:40 PM – 1:00 PM
Update on Medical Management of Prostate Cancer

6:30 AM – 11:00 AM
Exhibits open
7:00 AM – 7:05 AM
Welcome and Day 3 Program Overview
Breast Cancer – Session Chair - Hope S. Rugo, MD, FASCO
7:05 AM – 7:25 AM
Immunotherapy for Breast Cancer: Updates and New Directions
7:25 AM – 7:45 AM
Antibody Drug Conjugates: New Agents and Optimal Sequencing
7:45 AM – 8:05 AM
Endocrine Therapy and Targeted Agents for Early-Stage HR+ Breast Cancer
8:05 AM – 8:25 AM
Endocrine Therapy for Advanced Breast Cancer: Current and Future Strategies
Breast Board – Moderator - Hope S. Rugo, MD, FASCO
8:35 AM – 9:25 AM
Join Forces with our Breast KOLs and Participate in an Active Discussion on the Most Interesting Breast Cases
Product Theater
9:30 AM – 10:15 AM
Product Theater Breakfast Showcase (Non-CE)
10:15 AM – 10:30 AM
Visit Exhibits
Other Women’s Cancers – Session Chair – Don S. Dizon, MD, FACP, FASCO
10:30 AM – 10:50 AM
Ovarian Cancer: Beyond Carboplatin and Paclitaxel
10:50 AM – 11:10 AM
Role of ADCs in Gynecological Malignancies
11:10 AM – 11:30 AM
Current Status of Cervical Cancer Screening
11:30 AM – 11:50 AM
Q&A I Panel Discussion
11:50 AM – 11:55 AM
Closing Remarks

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Registration

Registration Type Early
01/01/2022 - 07/31/2022
Regular
08/01/2022 - 12/31/2022
Late
01/01/2023 - 02/10/2023
One-day
pass
Physician
$445.00
$545.00
$645.00
$250.00
Allied Health
$345.00
$445.00
$545.00
$200.00
Resident/Fellow
$295.00
$395.00
$495.00
$175.00
Industry
$995.00
$1,195.00
$1,595.00
$450.00
Press
$250.00

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Primo Demographics

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants from all oncology specialties, treating all disease sites involved in the care of patients with cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

PRIMO 2020
at a Glance

26 Conference Sponsors

The Practical Recommendations in Immuno and Molecular Oncology Meeting is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

JA Commendation Mark
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
IPCE Credit Logo

This activity was planned by and for the healthcare team, and learners will receive 12.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

The Medical Educator Consortium designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOC Logo

“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”

Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)

Nursing

The Medical Educator Consortium designates this activity for 12.25 contact hours.

Pharmacist

This Application-based activity has been approved for 12.25 contact hours (1.2 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-23-002-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Assistant

AAPA Cat1 CME logo

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURE POLICY

The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession. 

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.